Category Archives: Business of Biotech

Scientific American Worldview 2011 Preview – Three pioneers share keys to success for building biotech in emerging markets

Three biotech luminaries who have succeeded against all odds share their experiences building a biotech company from the ground up in Brazil, China and India. This year’s report will profile: Guilherme Emrich, FIR Capital (Brazil) Ge Li, WuXi Apptec (China) Kiran Mazumdar-Shaw, Biocon (India) Their opinions and advice on a diverse range of subjects is explored in a Q&A while their individual stories are told in accompanying profiles.  Don’t miss this special section in the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Keys to success for building biotech in emerging markets

Three biotech luminaries who have succeeded against all odds share their experiences building a biotech company from the ground up in Brazil, China and India. This year’s report will profile: Guilherme Emrich, FIR Capital (Brazil) Ge Li, WuXi Apptec (China) Kiran Mazumdar-Shaw, Biocon (India) Their opinions and advice on a diverse range of subjects is explored in a Q&A while their individual stories are told in accompanying profiles.  Don’t miss this special section in the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

ISO: Biotech Humanitarian

We are looking for biotech humanitarians for our annual Biotech Humanitarian Award. The award recognizes an everyday hero who has helped to heal, fuel or feed the planet through their work in biotechnology. Know someone that you feel should be recognized for their good works? Nominate someone at www.iambiotech.org/award through January 31, 2010. 2009 Biotech Humanitarian Dr. Jay Keasling, was nominated by a colleague at the University of California at Berkley. Just think, you or your Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , ,

The booming H1N1 vaccine market

The vaccine market is booming – and biotech companies are just one of the beneficiaries.  A recent Associated Press Article explains that an increase in government support and newer, better technologies are just a part of it.  Patients look to benefit from new vaccinations on the horizon for diseases such as Alzheimer’s, herpes, malaria, and perhaps even a universal flu vaccine. It was just last month at the BIO Investor Forum’s H1N1 panel that panelists Read More >

Business of Biotech  |  1 Comment  |  Email This Post
Tags: , ,

Perspectives on today’s IPO candidates

Some speculation is coming back into the sector but most movement in public markets is specialist driven, not generalist driven. What will it take to get the generalist investors in? Unfortunately, most IPO stocks since 2005 have underperformed and have left a bad taste in the mouths of generalists. This has left generalists believing they cannot just come into the sector and purchase a basket of young biotechs. Example of a successful IPO: Targacept filed Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,